Details of the Drug Reposition

General Information of This Drug (ID: DMMJTYW)

Drug Name
Darbepoetin alfa   DMMJTYW
Synonyms Aranesp (TN)
Therapeutic Class
Antianemic Agents

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Carcinoma DISH9F1N 2A00-2F9Z Approved [1]
------------------------------------------------------------------------------------
3 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Anemia DISTVL0C 3A00-3A9Z Investigative [2]
Chronic kidney disease DISW82R7 GB61 Investigative [3]
Nephropathy DISXWP4P GC2Z Investigative [4]
------------------------------------------------------------------------------------

References

1 DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group. Radiother Oncol. 2018 Apr;127(1):12-19.
2 Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84.
3 A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19;361(21):2019-32.
4 Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan. Clin Exp Nephrol. 2021 Feb;25(2):110-119.